CEO Özge Altunbaş Göktekin of VSY Biotechnology, a significant global company in the field of ophthalmology, gave us valuable information on cataract disease and solutions provided by the company’s new trifocal intraocular lenses. Altunbaş said: “With the help of the trifocal intraocular lenses we developed, we can offer a solution for both cataracts and eye defects.
VSY Biotechnology CEO Özge Altunbaş Göktekin stated that extraordinary developments observed recently in science and communication technologies have caused a transformation in the management approaches adopted by companies and added: “With technological advances transforming management ideas and approaches in enterprises, managers and employees now feel obliged to adopt a proactive, creative, and responsible role in their organization.”
We addressed our questions to VSY Biotechnology CEO Özge Altunbaş Göktekin about changing management approaches.
Presented at the ESCRS Satellite Symposium
VSY Biotechnology Offers “A New Approach to Trifocal Intraocular Lens Technology”
The European Cataract and Refractive Surgery Association held their 36th annual meeting from September 22nd to 26th, 2018. This meeting included an examination of trifocal intraocular lenses (IOLs) produced with advanced technology. Specifically, VSY Biotechnology shared the features and clinical results of AcrivaUD Trinova IOLs that they developed after extensive R&D studies.
The 36th ESCRS Congress will be organized by the European Cataract and Refractive Surgery Association in Wien/Austria on 22-26 September 2018. The Congress will enjoy the participation of international companies specialized in eye health who will present the latest innovations in the science of ophthalmology. While more than 10.000 visitors from all around the world are expected to attend the congress,
VSY Biotechnology took out a patent for a “Rotaryjet Preloaded Injector” enabling the easy, quick, and safe injection and implantation of intra-ocular lenses during cataract operations. The firm also became the owner of a patent for its new packing of intra-ocular lenses produced with biocompatible material that has strong sterilization characteristics.
In the “Rotaryjet Preloaded Injector,” which was invented and patented by VSY Biotechnology,
Osteoarthritis causes reduced movement and pain due to the disruption of the cartilaginous structures on the joint surface. New solutions offer treatments without surgery. One of the most important treatments recently accepted all over the world is intra-articular injection, which slows the progression of osteoarthritis.
Knee, hip, ankle, finger, and spinal joints are the sites in the body most commonly affected by osteoarthritis,
Over past eight years, 3 million people have been implanted VSY Biotechnology intraocular lenses through cataract surgeries, says CEO Ozge Altunbas Goktekin
Acriva Trinova lenses not only manage cataract, but also provides continuous sight on near, mid, far and intermediate ranges, CEO of the Netherlands based company VSY Biotechnology said.
VSY Biotechnology announced the launch of its Acriva Trinova Trifocal IOL (Figure 4) at the meeting. The Acriva Trinova is manufactured with VSY’s Seamless Vision Technology, a patent-pending technique that produces an optical surface with no sharp edges. The concept provides a continuous range of vision and helps to reduce halos and scattered light, according to VSY.
VSY Biotechnology Chairman Ercan Varlıbaş, M.D., visits the ASCRS Annual Meeting in Washington. Each year his company exports cataract lenses worth millions of dollars, VSY Biotechnology intraocular lenses have helped 3 million of people with eye problems, around the world to achieve clear vision.
Dr. Ercan Varlıbaş, Chairman of VSY Biotechnology, recently visited the American Cataract and Refractive Surgery Association (ASCRS) Annual Meeting and Scientific Session in Washington,
AcrivaUD Trinova: creating better visual outcomes with a sinusoidal approach to trifocality
Not all multifocal IOLs are equal. A crucial part of the conversation between a patient who wants a multifocal IOL and the surgeon is finding out the patient’s ideal near and intermediate distances are – and then the multifocal IOL that would most closely match their preferences is selected.